Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

The FDA Should Have Approved Probuphine, But They Didn't... So Now What?

Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.

Shares of Titan Pharmaceuticals (NASDAQ:TTNP) have been stuck in a narrow trading range between $0.45 and $0.65 for the past 4+ months following the surprise decision from the U.S. FDA to issue a complete response letter (CRL) for Probuphine back in late April 2013. We call this decision by the FDA a "surprise", because only five weeks prior to the decision, in March 2013, the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted to recommend approval of the product. Titan plans to request a meeting with the FDA to discuss the issues raised in the CRL in the next few weeks....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details